Abstract

  Most of the patients referred to a specialized hepatology center suffer from decompensation of end-stage chronic liver disease or acute-on-chronic liver failure. A subset of patients with no pre-existing illness can present as acute liver failure. The only recommended treatment of choice is liver transplantation. Hence, it is important to understand the indications for liver transplantation, types of liver transplantation and a general overview of immunosuppression.

Keywords: Hepatology; Liver Transplantation; Liver Failure

References

1. Starzl TE., et al. “Homotransplantation of the liver in humans”. Surgery, Gynecology, and Obstetrics 117 (1963): 659-676.
2. D’Amico G. “The clinical course of cirrhosis. Population based studies and the need of personalized medicine”. Journal of Hepatology 60 (2014): 241-242.
3. D’Amico G., et al. “Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies”. Journal of Hepatology 44 (2006): 217-231.
4. Bernardi M., et al. “Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis”. Journal of Hepatology 63 (2015): 1272-1284.
5. Arvaniti V., et al. “Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis”. Gastroenterology 139 (2010): 1246-1256.
6. Child GC II and Turcotte JG. “Surgery and portal hypertension”. In: Child GC II, editor. The liver and portal hypertension. Philadelphia: Saunders (1964): 50-58. 
7. Pugh RN., et al. “Transection of the oesophagus for bleeding esophageal varices”. British Journal of Surgery 60 (1973): 646-649.
8. Kamath PS., et al. “A model to predict survival in patients with end-stage liver disease”. Hepatology 33 (2001): 464-470. 
9. Malinchoc M., et al. “A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts”. Hepatology 31 (2000): 864-871.
10. Schrier RW., et al. “Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis”. Hepatology 8 (1988): 1151-1157 .
11. Merion RM., et al. “The survival benefit of liver trans-plantation”. American Journal of Transplantation 5 (2005): 307-313.
12. Wiesner R., et al. “Model for end-stage liver disease (MELD) and allocation of donor livers”. Gastroenterology 124 (2003): 91-96. 
13. Freeman RB., et al. “Results of the first year of the new liver allocation plan”. Liver transplantation 10 (2004): 7-15.
14. Angeli P., et al. “Hyponatremia in cirrhosis: results of a patient population survey”. Hepatology 44 (2006): 1532-1542. 
15. Londono MC., et al. “MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation”. Gut 56 (2007): 1283-1290. 
16. Biggins SW., et al. “Evidence-based incorporation of serum sodium concentration into MELD”. Gastroenterology 130 (2006): 1652-1660. 
17. Kim WR and Biggins SW., et al. “Hyponatremia and mortality among patients on the liver transplant waiting list”. The New England Journal of Medicine 359 (2008): 1018-1026. 
18. Fallon MB., et al. “Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome”. Liver Transplantation 12 (2006): S105-S107.
19. Krowka MJ., et al. “Model for end-stage liver disease (MELD) exception for porto-pulmonary hypertension”. Liver Transplantation 12 (2006): S114-S116.
20. Mazzaferro V., et al. “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis”. The New England Journal of Medicine 334 (1996): 693-699.
21. Yao FY., et al. “Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival”. Hepatology 33 (2001): 1394-1403.
22. Pomfret EA., et al. “Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States”. Liver Transplantation 16 (2010): 262-278. 
23. Sasaki K., et al. “Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective analysis”. The Lancet Gastroenterology and Hepatology 2.8 (2017): 595–603.
24. The European Association for the Study of the Liver. “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis”. Journal of Hepatology (2018).
25. Machiano VI. “Model for end stage liver disease-sodium score”. Clinical Liver Disease 21 (2017): 275-287.
26. Bernal W., et al. “Acute liver failure”. Lancet 376 (2010): 190-201. 
27. O’Grady JG., et al. “Acute liver failure: redefining the syndromes”. Lancet 342 (1993): 273-275. 
28. O’Grady JG., et al. “Early indicators of prognosis in fulminant hepatic failure”. Gastroenterology 97 (1989): 439-445. 
29. Sen S., et al. “The pathophysiological basis of acute-on-chronic liver failure”. Liver 22.2 (2002): 5-13.
30. Sarin SK., et al. “Acute-on-chronic Liver Failure (ACLF): Consensus Recommendations of the Asian Pacific Association for the Study of the Liver (APASL)”. Hepatology International 3 (2009): 269-282.
31. Moreau R., et al. “Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis”. Gastro 144 (2013): 1426-1437.
32. Choudhary A., et al. “Liver failure determines the outcome in patients with acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models”. Hepatology International 11.5 (2017): 461-471.
33. Khanna R., et al. “Neonatal cholestasis with ductal paucity and steatosis”. Indian Pediatrics 50 (2013): 316-320.
34. Deirdre Kelly. Diseases of the Liver and Biliary System in Children 2008.
35. Berg CL., et al. “Improvement in survival associated with adult-to-adult living donor liver transplantation”. Gastroenterology 133 (2007): 1806-1813. 
36. Merrill JP., et al. “Successful transplantation of kidney from a human cadaver”. Journal of the American Medical Association 185 (1963): 347-353.
37. A definition of irreversible coma Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. Journal of the American Medical Association 205.6 (1968): 337-340.
38. Feng S., et al. “Characteristics associated with liver graft failure: the concept of a donor risk index”. American Journal of Transplantation 6 (2006): 783-790.
39. Lopez-Navidad A and Caballero F. “Extended criteria for organ acceptance. Strategies for achieving organ safety and for increasing organ pool”. Clinical Transplantation 17 (2003): 308-324.
40. Bismuth H and Houssin D. “Reduced-size orthotopic liver graft for liver transplantation in children”. Surgery 95 (1984): 367-370.
41. Carrera MT., et al. “Domino liver transplantation: a practical option in the face of the organ shortage”. Progress in Transplantation 13 (2003): 151-153. 
42. Yamamoto S., et al. “Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single center experience over 16 years”. American Journal of Transplantation 7(11) (2007): 2597-2604. 
43. Rammohan A., et al. “Auxiliary partial orthotopic liver transplantation for selected noncirrhotic metabolic liver disease”. Liver Transplantation 25.1 (2019): 111-118.
44. Vilatoba M., et al. “New immunosuppressive strategies in liver transplantation: balancing efficacy and toxicity”. Current Opinion in Organ Transplantation 8 (2003): 139-145.
45. Wiesner RH., et al. “Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome”. Hepatology 28 (1998): 45.
46. Neuberger J and Adams DH. “What is the significance of acute liver allograft rejection?”. Journal of Hepatology 29 (1998): 143-150.
47. Lowes JR., et al. “Chronic rejection of the liver allograft”. Gastroenterology Clinics of North America 22 (1993): 401-420. 
48. Mueller XM. “Drug immunosuppression therapy for adult heart transplantation. Part 1. Immune response to allograft and mechanism of action of immunosuppressants”. The Annals of Thoracic Surgery 77 (2004): 354-362. 
49. Pfeilschifter J and Muhl H. “Immunopharmacology: anti-inflammatory therapy targeting transcription factors”. European Journal of Pharmacology 375 (1999): 237-245. 
50. Varghese J., et al. “Tacrolimus related adverse effects in liver transplant recipients: its association with trough concentrations”. Indian Journal of Gastroenterology 33.3 (2014): 219-225.
51. Jiang H and Kobayashi M. “Differences between cyclosporin A and tacrolimus in organ transplantation”. Transplantation Proceedings 31 (1999): 1978-1980.
52. Nielsen OH., et al. “The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine”. Alimentary Pharmacology and Therapeutics 15 (2001): 1699-708.
53. Moreno JM., et al. “Usefulness of mycophenolate mofetil in patients with chronic renal insufficiency after liver transplantation”. Transplantation Proceedings 35 (2003): 715-717.
54. Koehl GE., et al. “Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice”. Transplantation 77 (2004): 1319-1326. 
55. Trotter JF. “Sirolimus in liver transplantation”. Transplantation Proceedings 35 (2003): S193-200.
56. Tan HP., et al. “Everolimus: an update”. Current Opinion in Organ Transplantation 8 (2003): 323-326.

Citation

Citation: Chandan Kumar Kedarisetty., et al. “Understanding the Basic Concepts of Liver Transplantation”. Acta Scientific Gastrointestinal Disorders 3.2 (2020): 25-33.

Copyright

Copyright: © 2020 Chandan Kumar Kedarisetty., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.